View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Dec. 21 (HealthDay News) -- Approval for the HIV drug Isentress (raltegravir) has been expanded to include children and adolescents ages 2 to 18, the U.S. Food and Drug Administration said Wednesday.
The drug is an integrase strand transfer inhibitor that helps slow the spread of the AIDS-causing virus throughout the body, the agency said in a news release. It was first approved for adults in October 2007.
The twice-daily pill is available in a chewable form for people aged 2 to 11, and in a non-chewable form. Clinical testing of the drug among 96 children and teens with HIV-1 infection showed 53 percent of patients had undetectable blood HIV levels after 24 weeks, the FDA said.
The most common reported side effects of Isentress included trouble sleeping and headache.
The drug does not cure HIV infection, and patients must take Isentress continually to ensure ongoing reduction in HIV-related illness, the FDA stressed.
The drug is produced by Merck & Co., based in Whitehouse Station, N.J.
The U.S. Department of Health and Human Services has more about HIV/AIDS.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top